| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1830 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 287 | 2021 |
| Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ... Cancer discovery 10 (10), 1514-1527, 2020 | 142 | 2020 |
| COVID-19 vaccination and breakthrough infections in patients with cancer AL Schmidt, C Labaki, CY Hsu, Z Bakouny, N Balanchivadze, SA Berg, ... Annals of oncology 33 (3), 340-346, 2022 | 90 | 2022 |
| The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome PK Yang, CY Hsu, MJ Chen, MY Lai, ZR Li, CH Chen, SU Chen, HN Ho The Journal of Clinical Endocrinology & Metabolism 103 (3), 890-899, 2018 | 57 | 2018 |
| COVID-19 and Cancer Consortium NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study …, 2020 | 55 | 2020 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 40 | 2021 |
| Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 30 | 2023 |
| Immune‐related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration‐approved indications for … S Das, KK Ciombor, S Haraldsdottir, Y Pumpalova, IH Sahin, G Pineda, ... The oncologist 25 (8), 669-679, 2020 | 30 | 2020 |
| The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19 A Li, NM Kuderer, CY Hsu, Y Shyr, JL Warner, DP Shah, V Kumar, S Shah, ... Journal of thrombosis and haemostasis 19 (10), 2522-2532, 2021 | 28 | 2021 |
| Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and … TK Choueiri, C Labaki, Z Bakouny, CY Hsu, AL Schmidt, G de Lima Lopes, ... The Lancet Regional Health–Americas 19, 2023 | 27 | 2023 |
| Scientific rigor in the age of COVID-19 Y Shyr, LD Berry, CY Hsu JAMA oncology 7 (2), 171-172, 2021 | 19 | 2021 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer cell 38 (6), 761-766, 2020 | 18 | 2020 |
| COVID-19 and Cancer Consortium DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ... Utilization of COVID-19 treatments and clinical outcomes among patients with …, 2020 | 18 | 2020 |
| Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19 SM Rubinstein, D Bhutani, RC Lynch, CY Hsu, Y Shyr, S Advani, ... Blood cancer discovery 3 (3), 181-193, 2022 | 14 | 2022 |
| Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer PC Mack, JE Gomez, AM Rodilla, JM Carreño, CY Hsu, C Rolfo, ... Cancer Cell 40 (6), 575-577, 2022 | 13 | 2022 |
| Analysis of cancer survival associated with immune checkpoint inhibitors after statistical adjustment: a systematic review and meta-analyses EPY Lin, CY Hsu, L Berry, P Bunn, Y Shyr JAMA network open 5 (8), e2227211-e2227211, 2022 | 12 | 2022 |
| Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy. S Das, KK Ciombor, S Haraldsdottir, YS Pumpalova, IH Sahin, Y Shyr, ... Journal of Clinical Oncology 37 (15_suppl), 4116-4116, 2019 | 12 | 2019 |
| Scalable and model-free detection of spatial patterns and colocalization Q Liu, CY Hsu, Y Shyr Genome research 32 (9), 1736-1745, 2022 | 11 | 2022 |
| Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). MD Tucker, AL Schmidt, CY Hsu, Y Shyr, AJ Armstrong, Z Bakouny, ... Journal of Clinical Oncology 39 (6_suppl), 39-39, 2021 | 11 | 2021 |
